Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dateng, Xu, Meng, Hooper, Andrea T., Rofail, Diana, Mohammadi, Kusha A., Chen, Yiziying, Ali, Shazia, Norton, Thomas, Weinreich, David M., Musser, Bret J., Hamilton, Jennifer D., Geba, Gregory P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/
https://www.ncbi.nlm.nih.gov/pubmed/37550377
http://dx.doi.org/10.1038/s41598-023-39681-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/
https://www.ncbi.nlm.nih.gov/pubmed/37550377
http://dx.doi.org/10.1038/s41598-023-39681-7

Ejemplares similares